ICON plc (NASDAQ:ICLR), a leading global provider of outsourced drug and device development and commercialization services with an adjusted market capitalization of $13.8 billion, faces a complex ...
The DCF model suggests that ICON is undervalued by 98.23%. Between 2018 and 2024, the company's revenues increased by 219.04% and by 145.30%, respectively. This year, ICLR will implement a program to ...
Tuesday, TD Cowen reaffirmed its Buy rating and $285.00 price target on ICON plc shares (NASDAQ:ICLR), following the company's financial guidance. According to InvestingPro analysis, ICON currently ...
ICON PLC (NASDAQ:ICLR) reported its Q3 2025 earnings, surpassing analysts’ expectations with an EPS of $3.31, slightly above the forecast of $3.30. Revenue also exceeded projections, reaching $2.043 ...
Let us help you with your inquiries, brochures and pricing requirements Request A Quote Download PDF Copy Download Brochure The ICON Analyzer device is designed to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback